Combination of tadalafil and finasteride for improving the symptoms of benign prostatic hyperplasia: critical appraisal and patient focus

References

• VerhammeKMDielemanJPBleuminkGSfor Triumph Pan European Expert PanelIncidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care – the Triumph projectEur Urol200242432332812361895
   PubMed Web of Science ®Google Scholar
• IrwinDEMilsomIHunskaarSPopulation-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC studyEur Urol20065061306131417049716
   PubMed Web of Science ®Google Scholar
• CoyneKSSextonCCThompsonCLThe prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) studyBJU Int2009104335236019281467
   PubMed Web of Science ®Google Scholar
• IrwinDEKoppZSAgatepBMilsomIAbramsPWorldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstructionBJU Int201110871132113821231991
   PubMed Web of Science ®Google Scholar
• McConnellJDRoehrbornCGBautistaOMfor Medical Therapy of Prostatic Symptoms (MTOPS) Research GroupThe long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasiaN Engl J Med2003349252387239814681504
   PubMed Web of Science ®Google Scholar
• Cialis^® (tadalafil) [package insert]Indianapolis, IN, USAEli Lilly and Company 2011
   Google Scholar
• McVaryKTRoehrbornCGAvinsALUpdate on AUA guideline on the management of benign prostatic hyperplasiaJ Urol201118551793180321420124
   PubMed Web of Science ®Google Scholar
• OelkeMBachmannADescazeaudAGuidelines on the management of male lower urinary tract symptoms (LUTS), including benign prostatic obstruction (BPO)Eur Urol201364111814023541338
   PubMed Web of Science ®Google Scholar
• van KerrebroeckPJardinALavalKUvan CanghPEfficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study GroupEur Urol200037330631310720857
   PubMed Web of Science ®Google Scholar
• ChappleCRWyndaeleJJNordlingJBoeminghausFYpmaAFAbramsPTamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicenter studies in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study GroupEur Urol19962921551678647141
   PubMed Web of Science ®Google Scholar
• McConnellJDBruskewitzRWalshPThe effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study GroupN Engl J Med199833895575639475762
   PubMed Web of Science ®Google Scholar
• RoehrbornCGBoylePNickelJCHoefnerKAndrioleGfor ARIA3001 ARIA3002 and ARIA3003 Study InvestigatorsEfficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasiaUrology200260343444112350480
   PubMed Web of Science ®Google Scholar
• RoehrbornCGSiamiPBarkinJfor CombAT Study GroupThe effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT studyEur Urol201057112313119825505
   PubMed Web of Science ®Google Scholar
• GiulianoFÜckertSMaggiMBirderLKisselJViktrupLThe mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasiaEur Urol201363350651623018163
   PubMed Web of Science ®Google Scholar
• MorelliASarchielliEComeglioPPhosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive ratsJ Sex Med20118102746276021812935
   PubMed Web of Science ®Google Scholar
• AnderssonKEde GroatWCMcVaryKTTadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of actionNeurourol Urodyn201130329230121284024
   PubMed Web of Science ®Google Scholar
• GacciMEardleyIGiulianoFCritical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasiaEur Urol201160480982521726934
   PubMed Web of Science ®Google Scholar
• PorstHKimEDCasabéARfor LVHJ Study TeamEfficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial. Eur Urol20116051105111321871706
   PubMed Web of Science ®Google Scholar
• RoehrbornCGChappleCOelkeMCoxDEslerAViktrupLEffects of tadalafil once daily on maximum urinary flow rate in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasiaJ Urol201419141045105024445278
   PubMed Web of Science ®Google Scholar
• OelkeMGiulianoFMironeVXuLCoxDViktrupLMonotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomized, parallel, placebo-controlled clinical trialEur Urol201261591792522297243
   PubMed Web of Science ®Google Scholar
• McNicholasTAKirbyRSLeporHEvaluation and nonsurgical management of benign prostatic hyperplasiaWeinAJCampbell-Walsh UrologyPhiladelphia, PA, USASaunders Elsevier2011
   Google Scholar
• BecharaARomanoSCasabéAComparative efficacy assessment of tamsulosin vs tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot studyJ Sex Med2008592170217818638006
   PubMed Web of Science ®Google Scholar
• SinghDVMeteUKMandalAKSinghSKA comparative randomized prospective study to evaluate efficacy and safety of combination of tamsulosin and tadalafil vs. tamsulosin or tadalafil alone in patients with lower urinary tract symptoms due to benign prostatic hyperplasiaJ Sex Med201411118719624165272
   PubMed Web of Science ®Google Scholar
• RegadasRPRegesRCerqueiraJBUrodynamic effects of the combination of tamsulosin and daily tadalafil in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: a randomized, placebo-controlled clinical trialInt Urol Nephrol2013451394323108604
   PubMed Web of Science ®Google Scholar
• CasabéARoehrbornCGDa PozzoLFEfficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasiaJ Urol2014191372773324096118
   PubMed Web of Science ®Google Scholar
• EgerdieRBAuerbachSRoehrbornCGTadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind studyJ Sex Med20129127128121981682
   PubMed Web of Science ®Google Scholar
• GlinaSRoehrbornCGEsenASexual function in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: results of a 6-month, randomized, double-blind, placebo-controlled study of tadalafil coadministered with finasterideJ Sex Med201512112913825353053
   PubMed Web of Science ®Google Scholar
• Rapaflo^® (silodosin) [package insert]Parsippany, NJ, USAWatson Pharma, Inc 2013
   Google Scholar
• Flomax^® (tamsulosin) [package insert]Brunswick, NJ, USACitron Pharma LLC2014
   Google Scholar